Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant
2020-04-20 · 78 min · episode 732 · 18 entities
Asserted relationships
-
0.63
evidence rules-v4
Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant
-
0.55
evidence rules-v4
Feed author/publisher: Russ Roberts
-
0.55
evidence rules-v4
Feed author/publisher: Library of Economics and Liberty
-
0.40
evidence rules-v4
Feed category: Society & Culture
-
0.40
evidence rules-v4
Feed category: Science
-
0.40
evidence rules-v4
Feed category: Philosophy
-
0.40
evidence rules-v4
Feed category: Education
-
0.40
evidence rules-v4
Feed category: Courses
-
0.40
evidence rules-v4
Feed category: Social Sciences
Entities found in this episode
concepts 12
-
0.50
evidence rules-v4
Feed category: Society & Culture
-
0.50
evidence rules-v4
Feed category: Science
-
0.50
evidence rules-v4
Feed category: Philosophy
-
0.50
evidence rules-v4
Feed category: Education
-
0.50
evidence rules-v4
Feed category: Courses
-
0.50
evidence rules-v4
Feed category: Social Sciences
-
0.40
evidence rules-v4
Feed category: Society & Culture
-
0.40
evidence rules-v4
Feed category: Science
-
0.40
evidence rules-v4
Feed category: Philosophy
-
0.40
evidence rules-v4
Feed category: Education
-
0.40
evidence rules-v4
Feed category: Courses
-
0.40
evidence rules-v4
Feed category: Social Sciences
persons 5
-
0.70
evidence rules-v4
Feed author/publisher: Russ Roberts
-
0.70
evidence rules-v4
Feed author/publisher: Library of Economics and Liberty
-
0.66
evidence rules-v4
Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant
-
0.55
evidence rules-v4
Feed author/publisher: Russ Roberts
-
0.55
evidence rules-v4
Feed author/publisher: Library of Economics and Liberty
podcasts 1
-
0.63
evidence rules-v4
Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant
Episode description as stored
Oncologist, author, and podcaster Vinay Prasad talks about his book Malignant with EconTalk host Russ Roberts. Prasad lays out the conflicts of interest and scientific challenges that make drugs that fight cancer so disappointing at times. The conversation looks at how policy changes might improve the incentives facing doctors, pharmaceutical companies, and patients.